Home > Result Summaries: Compounds > GSK1322322 Result Summaries: GSK1322322 GSKStudy ID Phase Title Summary (Download) 111341 phase 1 A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects (0 citation(s)) 112034 phase 1 A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects (0 citation(s)) 112167 phase 1 An Open Label, Non-Randomized, Single dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (0 citation(s)) 112668 phase 1 A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects (1 citation(s)) 113376 phase 1 A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects (0 citation(s)) 113414 phase 2 A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection (0 citation(s)) 114539 n\a PGx345: Pharmacogenetic investigation of the impact of functional N-acetyl transferase variants on reversible ALT elevations in healthy subjects following repeat dosing with GSK1322322 (0 citation(s)) 116053 n\a PGx441: Exploratory safety evaluation of asymptomatic ALT elevation related to GSK132322 using subjects from PDF113414, PDF111341 and PDF112668 (0 citation(s)) 116352 n\a Molecular Characterization of Methicillin-Resistant Staphylococcus aureus isolates from the GSK132322 Phase II a Study (0 citation(s)) 116595 phase 1 A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of ThreeFormulations and Food Effect on GSK1322322 in Healthy Subjects (0 citation(s))
